Compare GSK plc (GSK) vs SkyWest Inc (SKYW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs SkyWest Inc — how do they compare? GSK plc trades at $46.54 (market cap $91.88B), while SkyWest Inc trades at $96.57 (market cap $3.75B). The key difference: GSK plc is far larger — about 24.5× SkyWest Inc's market cap, and GSK plc pays a 3.9% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and SkyWest Inc for 8 Days on average.
| GSK | SKYW | |
|---|---|---|
Market Cap | $91.88B | $3.75B |
Volume | 7,730,529 | 196,324 |
Sector | Health | Industrials |
52-Week High | $61.18 | $115.94 |
52-Week Low | $43.24 | $78.40 |
Typical Hold Time | 93 Days | 8 Days |
Enterprise Value | $111.88B | $5.54B |
Dividend Yield | 3.9% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
SkyWest (SKYW) trades at $96.52, down 0.12% with a bearish technical signal despite strong analyst support. The stock shows mixed earnings performance with Q1 2026 beating expectations but Q4 2025 and Q2 2026 missing estimates. Fundamentally, the company maintains solid profitability with 9.78% net margin and attractive valuation metrics including a P/E of 9.6. Recent news highlights fleet modernization efforts and expanding flying agreements while executives have been selling shares.
The outlook remains cautiously optimistic with a $112 consensus price target representing 16% upside potential. Key opportunities include fleet expansion and strong cash flow generation, while risks involve cost pressures and recent insider selling activity. The stock presents a value opportunity given its below-market valuation multiples and positive analyst coverage.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →
